Crinetics Pharmaceuticals, Inc. (CRNX) has a consensus analyst rating of Buy, based on 18 analysts covering the stock. Of those, 18 recommend buying, 0 recommend holding, and 0 recommend selling.
The analyst consensus price target for CRNX is $86.60, representing a +117.9% upside from the current price of $39.75. Price targets range from a low of $67.00 to a high of $105.00.
